Mobistix Junior Instant (Paracetamol)

Paracetamol, the active ingredient in Mobistix Junior Instant, is an Analgesic presented as an oral preparation for oral use. It reduces pain and fever in children and adolescents. GNH USA supplies Mobistix Junior Instant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Paracetamol acts as an analgesic and antipyretic, relieving discomfort associated with common conditions. - Pain: provides relief from mild to moderate pain such as musculoskeletal aches. - Fever: lowers elevated body temperature in febrile states. - Headache: alleviates tension‑type headaches in pediatric patients.

Paracetamol is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nausea: mild stomach upset after ingestion. - Rash: transient skin redness or itching. - Elevated liver enzymes: mild, reversible changes in laboratory tests.

Serious or Rare Side Effects: - Hepatotoxicity: severe liver injury, especially with overdose. - Stevens‑Johnson syndrome: rare severe skin reaction. - Anaphylaxis: immediate hypersensitivity with breathing difficulty. - Blood disorders: rare cases of thrombocytopenia or neutropenia.

Paracetamol should be used with awareness of specific safety considerations. - Dosage limits: adhere to recommended maximum daily amount to avoid toxicity. - Liver disease: avoid or use only under medical supervision in patients with hepatic impairment. - Alcohol use: limit intake as concurrent alcohol can increase liver risk. - Age restrictions: ensure product is appropriate for the child's age and weight. - Pregnancy and breastfeeding: consult a healthcare professional before use. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Paracetamol may interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Warfarin: increased anticoagulant effect, monitor INR closely. - High‑dose alcohol: heightened risk of liver injury.

Moderate Interactions (Monitor Closely): - Carbamazepine: may reduce paracetamol plasma levels. - Isoniazid: potential for additive hepatotoxicity. - Rifampicin: may increase metabolism, lowering efficacy. - Phenobarbital: may enhance hepatic clearance. - Certain antiretrovirals: monitor liver function during combined therapy.